Skip to main content
. Author manuscript; available in PMC: 2009 Oct 15.
Published in final edited form as: J Immunol. 2008 Oct 15;181(8):5199–5203. doi: 10.4049/jimmunol.181.8.5199

FIGURE 1.

FIGURE 1

Pretreatment of BM-DCs with CpG enhances CD8+ T cell activation and TCR triggering compared with peptide alone. BM-DCs were treated with gB-8P peptide and/or CpG and incubated with gBT-I CD8+ T cells for 8 h. T cell activation was analyzed by FCM. A, MFI values of CD25 and CD69 in CD8+ T cells with and without CpG treatment. Neg, Negative. B, Representative Vβ8 down-regulation on activated (CD25+) cells in the presence or the absence of peptide and CpG. C, Dose response of Vβ8 down-regulation by gBT-I CD8+ T cells depicted as the percentage relative to unpulsed DCs for each treatment. Results representative of at least four experiments. *, p < 0.05.